Worth $14 million, entails providing project management and administrative oversight as the IRB of record for Biorepository Protocol and NIAID studies.
Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
Margrethe Sørgaard offers 25 years’ experience in leading positions in clinical development and operation, medical affairs and drug safety/pharmacovigilance.
This webinar on May 1 will explore several alternative clinical supply models, use cases and identify key considerations when adopting one of these models.
This webinar will cover how headspace methods are developed and validated for a variety of product-container configurations including pre-filled syringes.
This webinar on May 1 will explore several alternative clinical supply models, use cases and identify key considerations when adopting one of these models.
New joint venture aims to cover the entire drug discovery process, spanning early drug discovery research through the inception of drug discovery startups.
The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.
This webinar will cover how headspace methods are developed and validated for a variety of product-container configurations including pre-filled syringes.